CSPC Innovation Pharmaceutical (300765.SZ): SYS6051 injection has obtained drug clinical trial approval.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlling subsidiary, CSPC PHARMA Jiushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jiushi Biopharm"), recently received the Drug Clinical Trial Approval Notice for SYS6051 issued by the National Medical Products Administration, and will soon commence clinical trials. SYS6051 is a targeted antibody-drug conjugate against Tissue Factor (TF) in human tissues, which can bind to tissue factor on the surface of tumor cells, enter the cells through endocytosis, and release toxins to kill tumor cells. This product has been classified as a Category 1 biological product for therapeutic use. The approved indication for this trial is advanced solid tumors. Preclinical studies have shown that SYS6051 has a good anti-tumor effect on various cancers, and is expected to demonstrate significant therapeutic effects in subsequent clinical trials.